Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.
J Drugs Dermatol
; 11(12): 1498-501, 2012 Dec.
Article
in En
| MEDLINE
| ID: mdl-23377523
ABSTRACT
BACKGROUND:
Patients with psoriasis who are treated with systemic and biologic therapies may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that modulate CD4+ T cell subsets, including interleukin (IL)-12 and IL-23, have been suggested to play a role in the pathogenesis of HBV infection.OBJECTIVE:
To report the first known cases of acute HBV infection in 2 ustekinumab-treated patients with psoriasis from a phase 3 (PHOENIX 1) and a phase 4 (TRANSIT) study.RESULTS:
Both ustekinumab-treated patients generated an immune response toward HBV and experienced typical courses of infection, without progression to chronic HBV infection.CONCLUSION:
Continued monitoring of liver-related adverse events in clinical trials, registries, and spontaneous reporting from the postmarketing setting will further contribute to understanding the role of ustekinumab in viral hepatitis.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Antibodies, Monoclonal, Humanized
/
Hepatitis B
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
J Drugs Dermatol
Journal subject:
DERMATOLOGIA
Year:
2012
Document type:
Article
Affiliation country:
United States